🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Nurix Therapeutics, Inc. NRIX R2K

Healthcare · Biotechnology · United States
https://www.nurixtx.com

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

READ MORE ›
$17.76
+67.07% 1Y

Market & Price

Market Cap
$1.84B
Current Price
$17.76
High / Low (52W)
$21.47 / $8.24
Beta
1.88

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$4.65
Price to Book
3.82
P/S
25.59
EV/EBITDA
-4.41
Dividend Yield
-

Profitability & Returns

ROCE
-47.48%
ROE
-61.40%
ROA
-31.50%
Profit Margin
0.00%
Op Margin
-
EPS (Latest Qtr)
$-0.79
EPS (TTM)
$-3.17

Balance Sheet & Liquidity

Debt/Equity
0.12
Quick Ratio
5.89
Current Ratio
6.01
Debt
$58.66M
Total Assets
$688.13M
Current Assets
$606.82M
Working Capital
$520.35M

Ownership

Promoter Holding
1.09%
Chg in Prom Hold
-
FII / Inst Holding
114.88%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$1.35B
Total Revenue (TTM)
$71.78M
EBITDA
$-307.31M
Free Cash Flow
$-145.46M
Operating Cash Flow
$-260.29M
Shares Outstanding
103.41M
Gross Margin
0.00%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
29.55%
Profit 5Y
-15.54%
Revenue (YoY)
-66.10%
Earnings (YoY)
-

PROS

  • Compounding revenue at 29.5% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Earnings shrank at -15.5% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 NRIX Nurix Therapeutics, Inc. R2K 17.76 - $1.84B - -47.48% -61.40% 29.55% -15.54%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
⚙Ad space

Quarterly Results

Figures in USD.

Metric Feb 2019May 2019Aug 2019Nov 2019Feb 2020May 2020Aug 2020Nov 2020Feb 2021May 2021Aug 2021Feb 2022May 2022Aug 2022Feb 2023May 2023Aug 2023Feb 2024May 2024Aug 2024Nov 2024Feb 2025May 2025Aug 2025Nov 2025Feb 2026
Revenue ---------------30.68M18.47M16.59M12.09M12.59M-18.45M44.06M7.89M13.58M6.25M
Cost of Revenue --------------------------
Gross Profit --------------------------
Operating Expenses ---------------------81.32M92.38M99.28M96.67M98.75M
Operating Income ---2.61M--12.55M-13.23M-19.19M--24.52M-26.41M-29.00M-42.74M-45.72M-46.72M-42.95M-26.77M-40.01M-45.22M-48.54M-54.61M--62.86M-48.32M-91.39M-83.09M-92.50M
EBITDA ----------------------58.74M-43.23M-86.39M-78.46M-88.72M
Interest Expense --------------------------
Pretax Income ----------------------56.35M-42.70M-86.42M-78.22M-87.17M
Tax Provision --------------------8.00K0760.00K00-
Net Income -2.69M-3.07M-2.43M-13.52M-12.39M7.58M-18.52M-19.91M-24.27M-26.38M-28.84M-42.53M-45.40M-45.71M-40.73M-24.28M-36.98M-41.52M-44.55M-48.96M--56.35M-43.46M-86.42M-78.22M-87.17M
Diluted EPS -----0.00-1.09---0.60-0.65-0.95-1.01-0.90-0.75-0.45-0.68-0.76-0.71-0.67--0.67-0.52-1.03-0.82-0.79
R&D Expense --11.01M-12.97M14.14M18.94M-23.00M25.99M30.91M43.14M47.49M47.76M45.82M45.76M47.86M50.01M48.92M55.48M-69.66M78.10M86.12M-84.14M

Profit & Loss (Annual)

Figures in USD.

Metric Nov 2019Nov 2020Nov 2021Nov 2022Nov 2023Nov 2024Nov 2025
Revenue ---38.63M76.99M54.55M83.98M
Cost of Revenue -------
Gross Profit -------
Operating Expenses ---222.49M232.05M267.58M369.65M
Operating Income -22.24M-64.98M-117.89M-183.87M-155.06M-213.03M-285.67M
EBITDA ----173.06M-141.41M-196.60M-266.81M
Interest Expense -------
Pretax Income ----180.36M-143.95M-193.30M-263.70M
Tax Provision ---00270.00K760.00K
Net Income -21.70M-43.24M-117.19M-180.36M-143.95M-193.57M-264.46M
Diluted EPS ---2.73-3.71-2.65-2.88-3.05
R&D Expense 45.02M66.49M116.43M184.50M189.15M221.63M316.90M

Compounded Sales Growth

5 Years:29.55%
1 Year:-66.10%

Compounded Profit Growth

5 Years:-15.54%
1 Year:-

Stock Price Performance

1 Year:+67.07%
6 Months:+4.47%
3 Months:+11.21%
1 Month:+6.92%

Balance Sheet (Annual)

Figures in USD.

Metric Nov 2018Nov 2019Nov 2020Nov 2021Nov 2022Nov 2023Nov 2024Nov 2025
Total Assets -44.05M396.34M-416.76M355.60M669.34M688.13M
Current Assets ----318.45M295.50M619.39M606.82M
Cash & Equivalents -34.82M119.36M-64.47M54.63M110.00M246.96M
Inventory --------
Receivables ---6.00M0---
Total Liabilities -53.57M106.07M-113.06M155.10M142.35M149.39M
Current Liabilities -16.14M44.54M-70.66M86.96M95.85M86.47M
Long Term Debt --------
Total Debt ----11.96M30.61M28.30M55.73M
Total Equity -36.85M-57.71M290.27M-303.70M200.49M526.99M538.75M
Shares Outstanding ----47.17M48.72M75.87M101.81M

Cash Flows (Annual)

Figures in USD.

Metric Nov 2019Nov 2020Nov 2021Nov 2022Nov 2023Nov 2024Nov 2025
Operating Cash Flow 601.00K-80.00K--159.81M-81.36M-172.58M-249.47M
Investing Cash Flow 8.50M-254.40M-27.20M68.30M-257.71M147.85M
Financing Cash Flow 126.00K339.02M-117.19M3.22M485.67M238.64M
Capital Expenditure -1.65M-4.55M--12.24M-8.40M-9.27M-14.00M
Free Cash Flow -1.05M-4.63M--172.05M-89.77M-181.86M-263.47M
Net Change in Cash ----15.42M-9.85M55.37M137.03M

Ratios (Annual)

Figures in %.

Metric Nov 2019Nov 2020Nov 2021Nov 2022Nov 2023Nov 2024Nov 2025
Gross Margin % -------
Operating Margin % ----476.0%-201.4%-390.5%-340.2%
Net Margin % ----466.9%-187.0%-354.9%-314.9%
ROE % 37.6%-14.9%--59.4%-71.8%-36.7%-49.1%
ROCE % -79.7%-18.5%--53.1%-57.7%-37.1%-47.5%

Shareholding Pattern

Insiders
1.09%
Institutions
114.88%
Public Float
116.15%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 8.63% 8.93M $158.52M
2 Redmile Group, LLC 7.48% 7.73M $137.33M
3 Vestal Point Capital, LP 6.29% 6.50M $115.44M
4 Deep Track Capital, Lp 6.14% 6.35M $112.69M
5 FMR, LLC 5.36% 5.54M $98.41M
6 State Street Corporation 4.97% 5.14M $91.31M
7 Morgan Stanley 4.77% 4.93M $87.59M
8 Baker Bros. Advisors, LP 4.51% 4.66M $82.74M
9 Vanguard Capital Management LLC 4.28% 4.43M $78.63M
10 General Atlantic, L.P. 3.97% 4.10M $72.85M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for NRIX

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space